STAT3 and cancer: To overcome these limitations, we previously developed a strategy to deliver oligonucleotide-based STAT3 inhibitors, such as antisense oligonucleotides (ASOs), specifically into Toll-like receptor-9 (TLR9) expressing myeloid cells, B cells, and certain cancer cells (24).